Cases & Deals

Rgenix raises capital in $33 million Series B round

Clients Rgenix, Inc.

Jones Day represented Rgenix, Inc., a cancer therapeutics company developing first-in-class drugs targeting novel cancer pathways, in connection with its issuance of $33 million of Series B Preferred Stock in a private placement to Novo A/S, Sofinnova Partners, Partnership Fund for New York City, Alexandria Venture Investments, and Conegliano Ventures LP.